



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

The structure of the KlcA and ArdB proteins reveals a novel fold and antirestriction activity against Type I DNA restriction systems in vivo but not in vitro

Citation for published version:

Serfiotis-Mitsa, D, Herbert, AP, Roberts, GA, Soares, DC, White, JH, Blakely, GW, Uhrin, D & Dryden, DTF 2010, 'The structure of the KlcA and ArdB proteins reveals a novel fold and antirestriction activity against Type I DNA restriction systems in vivo but not in vitro' Nucleic Acids Research, vol. 38, no. 5, pp. 1723-1737. DOI: 10.1093/nar/gkp1144

Digital Object Identifier (DOI):

[10.1093/nar/gkp1144](https://doi.org/10.1093/nar/gkp1144)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Nucleic Acids Research

Publisher Rights Statement:

Copyright © 2010 The Author(s). Published by Oxford University Press. All rights reserved. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/2.0/uk/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



The structure of the KlcA and ArdB proteins reveals a novel fold and antirestriction activity against Type I DNA restriction systems *in vivo* but not *in vitro*

Dimitra Serfiotis-Mitsa¹, Andrew P. Herbert¹, Gareth A. Roberts¹, Dinesh C. Soares^{1,2}, John H. White¹, Garry W. Blakely³, Dušan Uhrín^{1,*} and David T. F. Dryden^{1,*}

¹EaStChem School of Chemistry, University of Edinburgh, The King's Buildings, Edinburgh, EH9 3JJ,

²Medical Genetics Section, Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU and ³School of Biological Sciences, The University of Edinburgh, The King's Buildings, Edinburgh EH9 3JR, UK

Received August 25, 2009; Revised November 17, 2009; Accepted November 18, 2009

ABSTRACT

Plasmids, conjugative transposons and phage frequently encode anti-restriction proteins to enhance their chances of entering a new bacterial host that is highly likely to contain a Type I DNA restriction and modification (RM) system. The RM system usually destroys the invading DNA. Some of the anti-restriction proteins are DNA mimics and bind to the RM enzyme to prevent it binding to DNA. In this article, we characterize ArdB anti-restriction proteins and their close homologues, the KlcA proteins from a range of mobile genetic elements; including an ArdB encoded on a pathogenicity island from uropathogenic *Escherichia coli* and a KlcA from an IncP-1b plasmid, pBP136 isolated from *Bordetella pertussis*. We show that all the ArdB and KlcA act as anti-restriction proteins and inhibit the four main families of Type I RM systems *in vivo*, but fail to block the restriction endonuclease activity of the archetypal Type I RM enzyme, EcoKI, *in vitro* indicating that the action of ArdB is indirect and very different from that of the DNA mimics. We also present the structure determined by NMR spectroscopy of the pBP136 KlcA protein. The structure shows a novel protein fold and it is clearly not a DNA structural mimic.

INTRODUCTION

DNA restriction and modification (RM) systems are widespread in bacteria and archaea, and function as defence

systems to reduce the influx of foreign DNA on mobile genetic elements via transduction, transformation and conjugation (1–3). The RM systems can be classified into four types, I–IV, depending upon their complexity of structure and function (2) with the Type I RM enzymes being the most complex exhibiting both restriction endonuclease and modification methyltransferase activities in one large complex although a sub-assembly can act as a monofunctional modification methyltransferase (4). These enzymes are composed of three subunits encoded by the genes *hsdR*, *hsdM* and *hsdS* (*hsd* denotes ‘host specificity of DNA’). HsdM (~50–60 kDa) and HsdS (~50 kDa) subunits comprise a methyltransferase (Mtase, M₂S₁), which in association with HsdR forms an endonuclease (R₂M₂S₁). The HsdR (~140 kDa) subunits are required for restriction, the HsdS subunit specifies the DNA target sequence and the HsdM subunits catalyses the methylation reaction. Depending upon the methylation state of the DNA, the RM complex can function as either an endonuclease (REase) or an Mtase. The REase will cleave incoming DNA that has not been appropriately modified by the Mtase. If the target sequence is unmodified (unmethylated) then it is targeted for restriction. If the target sequence is hemi-methylated, the unmethylated target strand also becomes methylated as well. Fully methylated DNA is immune to restriction. The Type I RM systems are further subdivided into families, five of which are defined at present by DNA hybridization, subunit complementation, antibody cross-reactivity and sequence conservation.

These complex Type I systems are found in over 50% of bacterial species (5) and this defence can be extremely strong (6). They therefore place a considerable

*To whom correspondence should be addressed. Tel: 0131 650 7061; Fax: 0131 650 7155; Email: dusan.uhrin@ed.ac.uk
Correspondence may also be addressed to David Dryden. Tel: 0131 650 4735; Fax: 0131 650 6453; Email: david.dryden@ed.ac.uk

evolutionary pressure on mobile genetic elements to evolve anti-restriction countermeasures encoded by the foreign DNA (2,3,7). One such measure is the use of anti-restriction proteins to modify or inactivate the RM system. These are frequently targeted against Type I RM systems and operate in a variety of different manners. The simplest anti-restriction proteins mimic the structure of DNA and include the proteins *ocr* from phage T7 and *ArdA* from plasmids and conjugative transposons (8,9). The *ocr* protein from phage T7 (9,10) and the *ArdA* proteins from conjugative plasmids and conjugative transposons (3,8,11–15) have been the most intensively studied of the DNA mimics. These inactivate the host's Type I RM enzyme by binding in the substrate (DNA) binding groove (16,17). The structure of these proteins shows they mimic DNA both in size and surface charge distribution and have high affinity for binding to the RM enzyme. Another group are single-strand DNA binding proteins and represented by the *ArdC* protein (7,18). Binding to the single-stranded DNA intermediate formed during conjugation seems to lead to anti-restriction though why this occurs is unclear as the Type I RM systems act on double-stranded DNA (11,18). The *ArdB* proteins (7,11,18) and their close homologues the *KlcA* proteins (19,20) are the subject of this study.

In annotated sequence databases, the *ArdB* proteins appear to be mostly confined to the proteobacteria. For instance, *Escherichia coli* K12 W3110 contains two prophages on its chromosome, CP4-6 and CP4-57, encoding *ardB* homologues termed *yafX* and *yjfX*, respectively (21). Comparison of the predicted products of these two genes with sequence databases indicates that they are highly homologous to the *ArdB* protein from the IncN incompatibility group conjugative plasmid pKM101 (11). Similarly, another putative *ardB*, ORF14, is encoded by the second pathogenicity island, PAI II_{CFT073}, from the uropathogenic *E. coli* CFT073 (22,23). Putative homologues have also been identified in *Legionella pneumophila* (24) and *Achromobacter denitrificans* (25). The *ArdB* proteins are small in size with an acidic nature, which is similar to *ocr* and *ArdA*. The anti-restriction function for *ardB* from pKM101 has been demonstrated but it was also observed that it did not inhibit modification (11) in contrast to the *ocr* and *ArdA* DNA mimics. This inability to block modification occurred despite the presence of the short 'anti-restriction amino acid motif' identified in *ocr*, *ArdA* and *ArdB* (7,26). The recent atomic structure of *ArdA* indicates that this motif has a structural role in maintaining the fold of *ArdA* rather than a direct role in inhibiting the RM enzyme (8). Therefore, the presence of this motif in *ArdB* does not necessarily imply a functional role.

klcA is one of three genes found on the *kilC* operon, one of four *kil* loci (20) found on IncP plasmids. Expression of *kil* genes can be lethal to *E. coli* and is regulated by the *kor* genes. *korA* and *korC* control *klcA* on the broad host range plasmid RK2. *klcA* from RK2 showed 31% identity and 56% similarity to *ardB* from pKM101. Plasmids of the incompatibility group P are found in a wide range of Gram-negative bacteria (27). IncP-1 β members usually carry multiple antibiotic resistance

determinants and genes for the degradation of xenobiotic compounds (28). An exception is the IncP-1 β plasmid pA1 from *Sphingomonas* sp. A1 that does not contain any of the typical accessory genes of IncP-1 β plasmids (29). Similarly, pBP136, isolated from *Bordetella pertussis* in a fatal case of whooping cough (19) was found to contain no accessory genes for antibiotic resistance, remnants of insertion sequences or transposons. It contains two regions involved in plasmid conjugation and a third region involved in plasmid replication, central control, stable inheritance and partitioning. This region contained a *klcA* gene encoding a protein with 71% identity to *KlcA* from RK2. Sequence alignment revealed that *KlcA* from pBP136 is also significantly related to the anti-restriction *ArdB* proteins (19) showing, e.g. 30% identity and 46% similarity to the 16.5 kDa *ArdB* from the IncN plasmid pKM101 (11). The significant homology of *KlcA* to *ArdB* implied a possible function of *KlcA* as an anti-restriction protein. However, *klcA* from the IncP-1 α plasmid RK2 showed no anti-restriction activity against the archetypal Type I RM system EcoKI from *E. coli* (20).

Here, we demonstrate that four *ardB* and two *klcA* display an anti-restriction function *in vivo* against Type I RM systems but contrary to expectations, we find that *in vitro*, the purified *ArdB* proteins are unable to prevent the normal restriction endonuclease activity of the EcoKI Type I RM enzyme indicating an anti-restriction mechanism distinct from the DNA mimicry used by the *ArdA* anti-restriction proteins (8,12,13). We present the NMR-derived atomic resolution structure of the full length, 142 amino acid, *KlcA* protein from plasmid pBP136 isolated from *B. pertussis* and show that it has a novel fold and clearly is not a DNA structural mimic.

METHODS

Strains, plasmids and genes

Escherichia coli JM109 was used as a general cloning strain (Promega Madison, WI, USA). The expression strain *E. coli* BL21(DE3) was purchased from Invitrogen (Groningen, The Netherlands). The *E. coli* strains used for assessing restriction activity *in vivo* comprise NM1261 (r⁻m⁻), NM1049 (restriction system Type IA), NK354 (Type IB), NK402 (Type IC), NM1009 (Type ID) and were a kind gift of Professor Noreen E. Murray (School of Biology, University of Edinburgh, UK). NM1041 (*hsd*⁺ *clpX*⁻) was again obtained from Noreen Murray (30). The NK and NM series were converted to DE3 lysogens as described previously (8).

Four *ArdB* genes were identified in the public sequence database held by the National Center for Biotechnology Information (Bethesda, MD, USA), Table 1. The gene sequences were then synthesised by GeneArt (Regensburg, Germany). The codon usage pattern was optimized in order to maximize expression yield in *E. coli*. To facilitate cloning, an NdeI restriction site was engineered to overlap the ATG start codon of each synthetic gene. In addition, a unique HindIII site was also included just downstream of the stop codon.

Table 1. The source of the *ardB* and *klcA* genes investigated

Identifier in NCBI protein database	Gene	Protein annotation	Our name	Organism	Amino acid length	Molecular weight including N-terminal methionine	Molar extinction coefficient M ⁻¹ cm ⁻¹	Predicted isoelectric point	Optimal protein expression temperature (°C)	Reference
NP_752219	<i>ORF14</i>	ArdB	ArdB _{CFT}	<i>E. coli</i> CFT073	157	17 832.1	34 410	4.83	37	(23)
ACB01415	<i>yafX</i>	ArdB	ArdB _{YAF}	<i>E. coli</i> K12/CP4-6 prophage	152	17 419.5	37 410	4.76	37	(21)
AAC75691	<i>yjfX</i>	ArdB	ArdB _{YFJ}	<i>E. coli</i> K12/CP4-57 prophage	152	17 303.3	37 410	4.64	37	(21)
YP_122202	<i>plpp0047</i>	ArdB	ArdB _{LP}	<i>L. pneumophila</i> str. Paris	134	15 409.5	26 740	5.05	25	(24)
BAF33451	<i>KlcA</i>	KlcA	KlcA ₁₃₆	<i>B. pertussis</i> BP136	142	15 659.6	22 900	4.84	30	(19)
NP_990889	<i>pEST4011_14</i>	KlcA	KlcA _{ADE}	<i>A. denitrificans</i>	144	16 026.8	21 620	4.74	30	(25)

The synthesised genes were then ligated into pET24a (kanamycin resistant) at the NdeI and HindIII sites of the expression vector and the anticipated sequence was verified by DNA sequencing on both strands. Two further *ardB* genes from *E. coli* DH5α (*yjfX* and *yafX*), Table 1, were PCR-amplified from genomic DNA and ligated into pET20b (Novagen, Madison, WI, USA). The primers used to amplify *yjfX* were: forward primer, 5'-ACGGTGTCATATGACAACACAGACACAGT-3'; reverse primer, 5'-GCTAGAATTCTTAATCAATAATGCGCAT-3'. The primers used to amplify *yafX* were: forward primer 5'-ACGGTGTCATATGACAACACAGACGCAGC-3'; reverse primer, 5'-GCTAGAATTCTCA GTCGATAATACGCAG-3'. The NdeI and EcoRI recognition sites used in the subsequent ligation are underlined. In both cases an amplified product of the expected size was obtained. The PCR products were then ligated into the NdeI and EcoRI sites of pET20b (ampicillin resistant). The sequence of the insert was verified to ensure no mistakes had been introduced during amplification. For assessing the effect of expressing *klcA*₁₃₆ in NM1041(DE3) (*hsd*⁺ *clpX*⁻) on growth in the presence and absence of 2-AP, *klcA*₁₃₆ was ligated into an expression vector with a carbenicillin selection marker (pET20b). This was achieved by digesting the KlcA₁₃₆ pET24a expression construct with NdeI and HindIII and ligating the insert into the corresponding sites of pET20b to produce pET20b-*klcA*₁₃₆.

The extinction coefficients of the proteins were calculated using the method of Gill and von Hippel (31), Table 1. All concentrations quoted for the proteins are based on the concentrations of monomers. The monomer molecular weights of the proteins are shown in Table 1 and include the N-terminal methionine.

Expression and purification of proteins

Escherichia coli BL21(DE3) cells were transformed with the recombinant plasmid and transformants selected using LB agar supplemented with 25 µg/ml kanamycin or 100 µg/ml carbenicillin. A single colony was picked and grown in LB medium plus 25 µg/ml kanamycin or 100 µg/ml carbenicillin at 37°C to an optical density at 600 nm (OD₆₀₀) of 0.5. Heterologous gene expression was induced by the addition of IPTG to 1 mM and the growth continued for a further 3 h at the temperature

given in Table 1 before harvesting. For four of the chosen genes, a prominent protein band corresponding to the predicted protein mass was visible on SDS-polyacrylamide gels of induced cells of BL21(DE3) containing the recombinant plasmid that was not visible in the negative control of the vector alone in BL21(DE3). The *A. denitrificans klcA* and *L. pneumophila ardB* could not be expressed at levels sufficient for purification. For protein production, a single colony of was used to inoculate 100 ml of LB medium supplemented with 25 µg/ml kanamycin or 100 µg/ml carbenicillin. The starter culture was grown to an OD₆₀₀ of 0.5–0.8 at 37°C and used to inoculate 10 L of LB containing 25 µg/ml kanamycin or 100 µg/ml carbenicillin and the cells grown at 37°C to an OD₆₀₀ of 0.5. Heterologous gene expression was induced as described above. Typically 50 g of cells were obtained from 10 l of culture. Cells were harvested by centrifugation (6000g, 4°C, 15 min) and the cell pellet was stored at –20°C until required.

Approximately 20 g of cell pellet was defrosted on ice for 30 min and resuspended in 200 ml buffer A (20 mM Tris-HCl pH 8.0, 7 mM 2-mercaptoethanol). A cocktail of protease inhibitors (Complete Protease Inhibitor Cocktail Tablet; Roche) was added to the cell suspension (1 tablet per 50 ml solution). The cells were disrupted by sonication on ice using a Soniprep 150 sonicator (Sanyo, Tokyo, Japan) fitted with a 9 mm diameter probe (5 × 1 min bursts with 15 s interval between each burst). The cell lysate was centrifuged at 20 000g for 1 h at 4°C and the supernatant was filtered through a 0.45 µm filter unit (Sartorius AG, Goettingen, Germany). The clarified extract was then loaded onto a 30 cm × 1 cm diameter DEAE anion exchange column equilibrated with buffer A, at a flow rate of 60 ml/h. The column was washed with ~3 column volumes of buffer A to remove unbound material. Bound proteins were then eluted using a 500 ml gradient of 0–0.7 M NaCl in buffer A at a flow rate of 20 ml/h. Fractions that gave a UV absorbance were subsequently analysed by SDS-PAGE and those containing ArdB were pooled and concentrated using a spin concentrator with a 5 kDa MWCO (VivaScience AG, Hannover, Germany) to a final volume of ~5 ml. The sample was then loaded on a Superdex-200 column (GE Healthcare, Uppsala, Sweden), equilibrated with buffer A + 0.2 M NaCl, and the protein was eluted at a flow rate of 10 ml/h. The fractions were subsequently

analysed by SDS-PAGE and those containing ArdB were pooled and concentrated. Purified ArdB/KlcA was stored at -20°C in buffer A supplemented with glycerol to 50% (v/v).

Analysis of proteins

The methods employed for assaying *ardB* activity *in vivo* used the efficiency of plating (eop) of phage lambda (virulent), λv , on the various strains of *E. coli* as described previously in detail (8,13). The NM and NK *E. coli* strains were transformed with the derivatives of pET24a or pET20b described above but protein overexpression was not induced. Instead, we relied upon the small amount of leaky expression to produce the anti-restriction proteins in sufficient quantity to demonstrate anti-restriction *in vivo*. All assays were performed in triplicate and at least 50 phage plaques per plate were counted. The standard deviation on the anti-restriction and anti-modification values is $\pm 25\%$.

To assess the possible role of the ClpXP in the anti-restriction behaviour of ArdB and KlcA, the ability of *E. coli* NM1041 (*hsd⁺ clpX⁻*) transformed with plasmids expressing *ardB* or *klcA* to survive on an agar plate containing 2-aminopurine (2-AP) was assessed (32). The strain will not grow in the presence of 2-AP unless the EcoKI RM system is inactivated by the production of active ArdB or KlcA. A single colony from an agar/carbenicillin plate of *E. coli* NM1041 transformed with either pET20b or pET20b-*klcA*₁₃₆ was streaked on an agar plate with or without 2-AP and incubated overnight at 37°C . This was repeated in triplicate with different colonies.

Fourier transform ion cyclotron mass spectrometry (33), isothermal titration calorimetry (10,13,33), size exclusion chromatography (34) and assays of EcoKI endonuclease activity (8,13,34) were performed as described previously. To investigate whether ArdB or KlcA interfered with the assembly of the EcoKI nuclease, 42 nM EcoKI Mtase and ~ 100 nM HsdR proteins (34) were incubated separately with a 20-fold excess of ArdB or KlcA in the nuclease reaction buffer for 2 min at 37°C . Equal volumes of these two samples were then mixed and pBRsk1 DNA added to 3 nM. After incubation of this reaction mix for 8 min at 37°C , the reaction was stopped as above.

NMR spectroscopy and structure calculations

The KlcA protein from *B. pertussis* was uniformly labelled with ^{15}N and ^{13}C by growing the recombinant strain in M9-minimal medium containing $^{15}\text{NH}_4\text{SO}_4$ and ^{13}C -D-glucose as the sole nitrogen and carbon sources, respectively. The labelled protein was purified as described above. Samples for NMR measurements contained 0.7 mM KlcA, 90% $\text{H}_2\text{O}/10\%$ D_2O and 0.05% NaN_3 in 20 mM deuterated sodium acetate buffer (pH 6.0).

All NMR experiments were carried out at 298 K unless stated otherwise on a Bruker AVANCE 800 MHz with a 5-mm triple resonance cryoprobe. NMR experiments for ^1H , ^{15}N and ^{13}C backbone and side-chain resonance

assignments included: two-dimensional (2D) ^1H - ^1H TOCSY, ^1H - ^1H NOESY, ^1H - ^{15}N HSQC, ^1H - ^{13}C HSQC, (HB)CB(CGCD)HD/(HB)CB(CGCDCE)HE, three-dimensional (3D) HNCO, HN(CA)CO, CBCANH, CBCA(CO)NH, HBHA(CO)NH, HBHANH, (H)CCH-TOCSY, H(CCO)NH, C(CO)NH (35). 3D ^{15}N - and ^{13}C -edited NOESY-HSQC spectra were acquired to obtain distance constraints (36,37). Aromatic $^1\text{H}^{\delta}$ and $^1\text{H}^{\epsilon}$ frequencies were obtained from (HB)CB(CGCD)HD/ (HB)CB(CGCDCE)HE spectra (38) where the aromatic ^1H frequencies are correlated with the assigned $^{13}\text{C}^{\beta}$ frequencies of the aromatic residue.

NMR data were processed using the Azara suite of programs (Wayne Boucher, Department of Biochemistry, University of Cambridge, UK, <http://www.ccpn.ac.uk/azara/>) and analysed using Ccpnmr Analysis (39). NOE assignments were generated during the initial rounds of structure analysis using CANDID (40) in CYANA 2.1 (41). Dihedral constraints were generated using TALOS (42). The NOE assignments obtained by CANDID were checked manually and from the 100 structures calculated, 20 structures with lowest target function were selected for further analysis. The structures were further refined with the incorporation of residual dipolar couplings (RDCs) using CNS (43). PROCHECK-NMR (44) and WHATIF (45) were used to analyse the quality of the structures. MOLMOL (46) and PYMOL (<http://www.pymol.org>) were used for visualisation.

A 200 μM ^{15}N -labelled KlcA sample in 20 mM deuterated sodium acetate, 0.05% NaN_3 , pH 6.0 in 90% $\text{H}_2\text{O}/10\%$ D_2O aligned with 6.25 mg/ml of Pfl filamentous phage (Pfl protease and RNase free, Profos) was used to measure RDCs. Magnetic alignment was monitored by 1D ^2H NMR spectra as a function of phage concentration. A 7 Hz residual quadrupolar splitting of the deuterium signal was achieved with 6.25 mg/ml phage. ^1H - ^{15}N splittings were measured under isotropic and partially aligned conditions using 2D IPAP ^1H - ^{15}N HSQC experiments (47). Analysis and back calculation of the RDCs were performed with REDCAT (48).

Relaxation experiments were performed on a 600 MHz Bruker Avance spectrometer at 25°C with 200 μM ^{15}N labelled KlcA. For the longitudinal (T_1) and transverse (T_2) relaxation data for the backbone ^{15}N nuclei of KlcA, water was kept along the z -axis during the entire pulse sequence (49) and extra delays were used in the T_1 experiment to eliminate differential heating arising from the variations of the relaxation delay (50). Eight interleaved spectra were recorded for each relaxation delay T_1 (51 twice, 401, 601, 801, 901, 1001 and 1201 ms) and T_2 (16 twice, 48, 64, 80, 96, 112 and 144 ms). T_1 and T_2 cross-peak intensities were measured from peak heights and fit to an exponential decay function $I(t) = I(0)e^{-Rt}$ where $I(0)$ and $I(t)$ are the cross-peak intensity at time 0 and time t , where time is the relaxation delay and R ($1/T$) is the relaxation rate (39). For the 2D ^1H - ^{15}N heteronuclear NOE experiment (49) a 3 s pre-saturation period and a 2 s relaxation delay was used; the control experiment had an equivalent 5 s delay. Spectra from the heteronuclear NOE experiment were extended by linear

prediction and zero filling prior to apodisation with a 5% shifted mixed Gaussian/exponential function. NOE peak heights were taken from the Gaussian fits of the frequency-domain data. The NOE was calculated as $\text{NOE} = I_{\text{on}}/I_{\text{off}}$ where I_{on} and I_{off} are the peak heights with and without ^1H pre-saturation, respectively. T_1 , T_2 and NOE data were fitted using 'Quadric_diffusion', (AG Palmer, Columbia University, NY, USA, <http://biochemistry.hs.columbia.edu/labs/palmer/software/quadric.html>) to obtain the rotational diffusion tensor. Model-free analysis of the relaxation data was performed using Tensor2 (51). For this analysis a subset of relaxation data was selected using criteria defined by Tjandra *et al.* (52). The relative moments of inertia were calculated with 'pdbinertia' (<http://biochemistry.hs.columbia.edu/labs/palmer/software/pdbinertia.html>) and the average rotational correlation time (τ_c) calculated with r2r1_tm (http://biochemistry.hs.columbia.edu/labs/palmer/software/r2r1_tm.html).

The complete set of coordinates for the structure has been deposited at the Protein Data Bank (PDB) (53) with accession code 2kmg and in the Biological magnetic resonance bank with code 16428.

Bioinformatics analysis of sequence and structure

Secondary structure was identified using STRIDE (54). Fold topology analysis was conducted using HERA (55) under PROMOTIF v2.0 (56) and schematically redrawn using TopDraw (57). The *B. pertussis* KlcA sequence was subjected to a BLAST search (58) against the PDB and to fold recognition server PHYRE (59) to check if there was any clear or remote homology to an existing structure or fold at the sequence level. Additionally, the 3D-coordinates of the KlcA structure were compared against 3D-fold and structure libraries using DALI (60) and SSM (61).

Sequences related to *B. pertussis* KlcA (UniProt Accession no: Q08L07) were obtained using a BLASTP search (58) against the UniProt sequence database (62), via the NPS@ server (63). A total of 182 sequences with an E-value of less than 10^{-6} were obtained and this list was made non-redundant initially by removing 62 identical sequences. The remaining 120 KlcA-like sequences were retrieved and a multiple sequence alignment was generated using the program PROMALS3D (64). This set of sequences was rendered further non-redundant by removing all 90% pairwise identical sequences in the alignment using the Expasy server (<http://www.expasy.ch/tools/redundancy/>). A total of 44 non-redundant divergent sequences were thus obtained. Upon analysis, one sequence that lacked the C-terminal helix 5 was discarded and three other sequences, which possessed N-terminal extensions, were trimmed. The remaining 43-aligned sequences were used as input for Consurf (65) (<http://consurf.tau.ac.il/>) to map sequence conservation on the surface of the protein. The electrostatic surface potential representation was calculated using GRASP (66). The lipophilic surface rendition was generated using MOLCAD (67) under SYBYL (Tripos Associates,

St Louis, MO, USA). Solvent-accessibility calculations were performed using GETAREA (68).

RESULTS

The ArdB proteins from the *E. coli* pathogenicity island, the CP4-6 prophage, the CP4-57 prophage and *L. pneumophila* will be referred to as ArdB_{CFT}, ArdB_{YAF}, ArdB_{YFJ} and ArdB_{LPP}, respectively. The KlcA proteins from *B. pertussis* and *A. denitrificans* will be referred to as KlcA₁₃₆ and KlcA_{ADE}, respectively. The names ArdB and KlcA without a subscript are to be understood as referring to all of the ArdB or KlcA studied.

Overexpression of klcA is not lethal to *E. coli*

It has been shown that unregulated expression of the *kil* genes leads to killing of the host cells. The cells become elongated with distorted outer membranes and macromolecular synthesis ceases (69). Previous studies of the *kilC* operon in plasmid RK2 showed that *klcA* was responsible for the lethality of *E. coli* host cells in the absence of *korA* and *korC* (20). However, we were able to overexpress the *klcA*₁₃₆ gene in a pET vector in the absence of *kor* determinants with no apparent harmful effects. Furthermore, *in vivo* anti-restriction experiments performed on the *klcA* from RK2 failed to identify any signs of anti-restriction function (20), whereas the *klcA*₁₃₆ and *klcA*_{ADE} showed efficient anti-restriction activity against all four families of Type I restriction systems as described below.

In vivo activity of *ardB* and *klcA* genes against the four families of Type I RM systems

The activity of anti-restriction genes can be tested by determining how many phages successfully infect a bacterial lawn in the presence or absence of host RM systems when the bacterium also contains a plasmid encoding the anti-restriction protein. All of the *ardB* and *klcA* genes except *ardB*_{LPP} showed significant levels of anti-restriction (>10-fold enhancement in the number of phage infections) despite their low levels of expression in the absence of induction, Table 2. The poor activity of the *ardB*_{LPP} and *klcA*_{ADE} genes were most likely due to poor expression as neither could be observed on SDS-PAGE. The effectiveness of the other proteins in inhibiting restriction matched levels observed for the ocr (9,10,15,70) and ArdA proteins (8,12,13) *in vivo* under similar conditions.

However, in contrast to ocr and ArdA, anti-modification by ArdB was generally very weak (<3-fold and negligible given the limitations of the assay), Table 2. In other words, the phages that escaped restriction were easily modified by the methylation activity of the RM system and ArdB had little if any inhibitory effect on methylation. In three cases, some inhibition of methylation was observed; ArdB_{CFT} and ArdB_{YFJ} slightly inhibited methylation by the Type ID RM system and ArdB_{YAF} slightly inhibited methylation by the Type IC RM system. These results show a clear difference

Table 2. Effect of expression of six different *ardB* and *klcA* on the RM of bacteriophage λv by four different Type I RM systems, each representing one of the four families (IA–ID) of Type I RM systems

Gene	Chromosomal restriction system in host <i>E. coli</i>							
	NM1049 Type IA EcoKI		NK354 Type IB EcoAI		NK402 Type IC EcoR124I		NM1009 Type ID StySBLI	
	Anti-restriction	Anti-modification	Anti-restriction	Anti-modification	Anti-restriction	Anti-modification	Anti-restriction	Anti-modification
<i>ardB</i> _{CFT}	710	2.0	54	1.8	199	1.3	1174	6.0
<i>ardB</i> _{YAF}	9250	1.4	27	1.6	7510	10.6	1080	1.5
<i>ardB</i> _{YFJ}	6160	1.2	10	1.1	251	1.0	1650	18.6
<i>klcA</i> _{ADE}	1140	1.6	14	1.2	13	1.9	37	1.2
<i>klcA</i> ₁₃₆	2430	1.4	76	1.1	628	3.1	969	1.4
<i>ardB</i> _{LPP}	270	1.1	17	1.1	1.9	1.4	132	1.4
Vector alone	1	1	1	2	1	2	1	1

The host *E. coli* contained a chromosomal copy of the RM system and an uninduced expression plasmid expressing *ardB* or *klcA* at low level. An anti-restriction or anti-modification value >2 was taken to indicate anti-restriction activity *in vivo*. Errors in the anti-restriction and anti-modification values are ± 25%.

between the activities of ArdB and KlcA compared to the DNA mimics, ocr and ArdA, suggesting that they use different mechanisms for interfering with the Type I RM systems.

KlcA₁₃₆ anti-restriction function does not involve the ClpXP protease

It has been shown that ClpXP-dependent regulation of the EcoKI endonuclease activity enables bacteria that acquire unmodified chromosomal target sequences to survive. When cells are under stress after prolonged exposure to treatments that damage DNA, such as exposure to 2-AP, the ClpXP-dependent pathway operates to prevent EcoKI from cleaving the chromosome (71). The restriction subunit of the nuclease (HsdR) is degraded in the presence of ClpXP (71). As described later, we did not observe any direct interaction of KlcA₁₃₆ with the EcoKI *in vitro*; therefore we tested the hypothesis that the anti-restriction activity of KlcA₁₃₆ was dependent on the ClpXP pathway. A *clpX*[−] mutant, NM1041(DE3), was plated in the presence and absence of 80 μg/ml 2-AP, Figure 1. The *clpX*[−] mutant was also transformed with the plasmid, pET20b-*klcA*₁₃₆, expressing *klcA*₁₃₆. As expected, the *clpX*[−] strain with no anti-restriction determinant present, grew well in the absence of 2-AP, but no growth was observed in the presence of 2-AP. In contrast, the *clpX*[−] strain carrying *klcA*₁₃₆ grew equally well in both the presence and absence of 2-AP. This finding indicates that KlcA₁₃₆ is able to block EcoKI restriction without involving the ClpXP protease. We assume that this result holds for ArdB and KlcA in general.

Solution state behaviour of ArdB and KlcA proteins

During purification it was noted that ArdB_{YAF} and ArdB_{CFT} behaved anomalously on a large volume (60 cm × 1.6 cm) Superdex 200 size-exclusion chromatography column despite showing only a single homogeneous species of the correct molecular weight on SDS-PAGE (data not shown) and mass spectrometry, Supplementary Table S1. Analysis with a small volume analytical column (25 cm × 0.46 cm) revealed two peaks corresponding to a dimer and a monomer for ArdB_{YAF} while ArdB_{CFT}




Figure 1. The effect of expressing KlcA₁₃₆ in a 2-AP sensitive strain of *E. coli*. A single colony of the ClpX[−] strain NM1041(DE3) harbouring either the KlcA expression construct (pET20b-*klcA*₁₃₆) or the corresponding vector alone (pET20b) was picked with a loop and spread onto an LB agar plate supplemented with 100 μg/ml carbenicillin, 25 μg/ml kanamycin in the absence (A) or presence (B) of 2-AP (80 μg/ml). The plates were then incubated at 37°C for 14 h.




Figure 2. An overlay of elution profiles for different proteins from a small volume (25 cm × 0.46 cm diameter) size exclusion chromatography column showing the variable quaternary structure of the four different proteins in 20 mM Tris, 20 mM MES, 0.2 M NaCl, 0.1 mM EDTA, 7 mM β-mercaptoethanol, pH 6.5: ArdB_{CFT} (black, 4 μM), ArdB_{YAF} (blue, 3 μM), ArdB_{YFJ} (red, 5 μM) and KlcA₁₃₆ (green, 4 μM). The proteins were detected using tryptophan fluorescence emission and are arbitrarily scaled vertically.

showed two peaks on the large volume column and a broad peak with shoulders on the small volume column, Figure 2. ArdB_{YFJ} and KlcA₁₃₆ showed only a single monomer peak. These results indicate that there was

genuine heterogeneity in the quaternary structure for two of the four proteins and the dependence on column volume for the ArdB_{CFT} protein further suggested that the apparent switching between the monomer and dimer forms was occurring on the minute timescale of the chromatography process.

***In vitro* activity of ArdB and KlcA₁₃₆ proteins against the EcoKI Type IA restriction endonuclease**

A circular plasmid containing a single copy of the target sequence for the EcoKI type I RM enzyme is efficiently cleaved by stoichiometric amounts of EcoKI in the presence of the essential cofactors SAM, ATP and Mg²⁺ resulting in a linearised plasmid (34). Stoichiometric amounts of the ocr and ArdA anti-restriction proteins inhibit this activity by binding strongly to and blocking the DNA binding site on EcoKI (9,12,13). Figure 3 shows that addition of a 20-fold excess of ocr or ArdA, expected to ensure complete inhibition, did indeed prevent any nuclease activity of the EcoKI restriction enzyme. Addition of the same concentration and degree of excess of any of the examined ArdB or KlcA₁₃₆ proteins to the endonuclease reaction showed no observable inhibition of the nuclease activity of EcoKI. Thus the anti-restriction activity clearly observed *in vivo* was not due to an anti-nuclease activity in contrast to what one might expect from the results of the anti-restriction assay. Hence, none of the ArdB or KlcA₁₃₆ tested appeared able to act as an inhibitor of the Type IA RM enzyme EcoKI in DNA cleavage. The order of addition of the reactants can be important for analysing Type I endonuclease activity. For instance ocr is unable to inhibit EcoKI if it is added after the DNA and ATP (72) so for this reason we added the DNA last to the mixture containing EcoKI, cofactors and anti-restriction protein to avoid this problem. Even with this precaution, ArdB and KlcA₁₃₆ were unable to influence the endonuclease activity of EcoKI.

KlcA₁₃₆ does not bind to EcoKI Mtase

Biophysical characterization using ITC and fluorescence spectroscopy performed on two other anti-restriction proteins, ocr and ArdA, have shown a strong interaction of the Mtase part of EcoKI with these proteins (13,16). However, ITC experiments performed at 10 and 25°C showed no apparent binding of KlcA₁₃₆ to Mtase, Figure 4. This result agrees with the *in vivo* modification assays where inhibition of phage DNA modification was not observed. Detecting the binding to the EcoKI nuclease was not feasible using ITC due to limited amounts of the nuclease. However, given the result of the nuclease inhibition assay, no interaction is expected with the surface of the nuclease.

Do KlcA and ArdB interfere with assembly of EcoKI?

Since the KlcA and ArdB proteins appear unable to interact neither with the complete EcoKI RM enzyme nor with the core Mtase *in vitro*, we also examined whether they could interact with the surface of the




Figure 3. Nuclease assay to test for inhibition of EcoKI by ArdB proteins. Lane 1, undigested DNA; lane 2, EcoKI digested DNA; lane 3, plus ocr; lane 4, plus Orf18 ArdA; lane 5, plus ArdB_{YAF}; lane 6, plus ArdB_{YFJ}; lane 7, plus KlcA₁₃₆; lane 8, plus ArdB_{CFT}; lane M, DNA ladder with sizes in kb. Plasmid DNA used was non-methylated pBRsk1. Ratio of the anti-restriction proteins (monomers) to EcoKI was 20:1. In each case the reaction mixture minus DNA was made up and incubated for 2 min at room temperature. The reaction was then initiated by adding DNA. Digestion was carried out for 8 min at 37°C before quenching at 68°C for 10 min. CC, closed circular plasmid; L, linear plasmid; OC, open circular plasmid.




Figure 4. Raw ITC data showing heat changes for the interaction of KlcA₁₃₆ with the EcoKI Mtase compared with data for the interaction of ArdB with the Mtase as previously published (13). The traces show from top to bottom: Mtase being titrated with ArdB at 25°C, buffer being titrated with Mtase at 25°C, Mtase being titrated with KlcA₁₃₆ at 25°C and Mtase being titrated with KlcA₁₃₆ at 10°C. It is clear that there is no interaction between the Mtase and KlcA₁₃₆.

HsdR restriction subunit of EcoKI that becomes buried on binding to the Mtase. This would interfere with the assembly of the complete RM enzyme as originally proposed by Belogurov and Delver (26). Addition of ArdB or KlcA prior to assembling the Mtase and HsdR into an intact EcoKI endonuclease failed to inhibit the endonuclease activity when DNA was subsequently added to the mixture, Figure 5. This strongly suggests that ArdB and KlcA do not interact with HsdR to interfere with assembly of EcoKI.

^1H , ^{15}N and ^{13}C chemical shift assignments and structure calculations for KlcA₁₃₆

The recorded ^1H - ^{15}N HSQC spectrum, Figure 6, was consistent with that of a folded protein exhibiting well dispersed signals and very little spectral overlap. Backbone and side-chain resonances of KlcA₁₃₆ were assigned based on 2D and 3D triple-resonance experiments. Peaks in the 3D ^{13}C and ^{15}N edited NOESY spectra were picked and the NOE cross-peak assignments were obtained from the automated iterative assignment program CANDID that works in conjunction with 3D structure calculations in the program CYANA 2.1.




Figure 5. The effect of adding ArdB or KlcA during the assembly of the EcoKI RM enzyme. Where relevant, Mtase and the R subunit were preincubated at 25°C in the presence of a $\times 20$ excess of ArdB or KlcA protein for ~ 5 min prior to mixing and addition of DNA. Reactions were performed at 37°C for 8 min. Lane 1, uncut pBRsk1 (3 nM); lane 2, pBRsk1 (3 nM) digested with EcoKI (30 nM); lane 3, pBRsk1 digested with reconstituted nuclease (equivalent to 30 nM EcoKI); lane 4, nuclease reconstituted in the presence of ArdB_{YAF} (20-fold excess over nuclease); lane 5, 20-fold excess ArdB_{YFJ}; lane 6, 20-fold excess KlcA₁₃₆; lane 7, pBRsk1 in the presence of R subunit only; lane 8, pBRsk1 in the presence of Mtase only. M, 1 kbp size marker.




Figure 6. 2D ^1H - ^{15}N HSQC spectrum of KlcA₁₃₆ at 800 MHz.

Using NOE restraints, TALOS dihedral restraints and ^1H - ^{15}N RDCs (Supplementary Figure S1), the lowest energy ensemble of 20 structures of KlcA₁₃₆ were calculated (Supplementary Figure S2). The calculations converged well, yielding root mean square deviations of 0.63 and 0.65 for backbone and all heavy atoms in structured regions (residues 7–142). Only a subset of RDCs, as specified in the 'Methods' section for the calculation of the rotational diffusion tensor, was used in the structure calculations. The structures were validated using PROCHECK and WHATIF. In the Ramachandran plot, 98.5% of residues appeared in the most favourable and additionally allowed regions. WHATIF packing analysis yielded an average quality control z -score of -1.432 suggesting a good quality NMR structure.

The structure of KlcA₁₃₆ reveals a rigid globular protein with a novel fold

The KlcA₁₃₆ protein structure is made up of a single domain (73) containing five α -helices (labelled 1–5), a single 3_{10} -helix and five β -strands (labelled A–E) and belongs to the mixed α/β class of proteins, Figure 7. The five β -strands form two separate beta-sheets, the first composed of anti-parallel β -strands A, B and C and the other made up of anti-parallel β -strands D and E. β -Strand A usually occurs as an isolated β -bridge from the ensemble consensus. The two β -sheets closely flank the C-terminal three α -helices (3–5) on either side. These three helices appear to run in an almost anti-parallel fashion to their helical axes in a classical knobs-in-holes arrangement of a three-helical bundle. Helix 3 is the longest of the helices located at the centre of the fold




Figure 7. KlcA₁₃₆ secondary and tertiary structure. Colour code: alpha-helices, red; beta-strands, yellow and 3₁₀ helix, purple. (A) Secondary structure elements identified by STRIDE for the ensemble consensus shown as a topology fold schematic (55–57). (B) A cartoon representation of the closest-to-mean 3D structure in the ensemble. Note: loops are rendered smooth for clarity.

and contains several hydrophobic amino acids at its N-terminus that are deeply buried. A stereo view of the ensemble of the 20 lowest energy structures of KlcA₁₃₆ is shown in Supplementary Figure S2.

Querying 3D-fold libraries and the PDB with the NMR-determined KlcA₁₃₆ 3D-structure demonstrated that its fold is novel, based upon its overall spatial arrangement and connectivity of secondary structure elements. For example, the strongest structural similarity found (z-score 5.1) using a DALI search of the PDB is to a discontinuous C-terminal portion of the 257-residue chain from G1/S-specific cyclin-D1 (PDB ID: 2W9Z), which is a purely α -helical protein. Although the z-score indicates structural similarity, the structurally aligned portions require a large 37-residue insertion between helices 2 and 3 (with respect to KlcA₁₃₆) that encompass β -strands B–E, which are absent in the cyclin structure. Further confirmation of the novelty of fold was obtained using SSM. These results are consistent with the lack of sequence identity/significance scores for the *B. pertussis* KlcA sequence against PDB sequences using a BLAST search, or remote similarity to any existing folds, when undertaking fold recognition.

In the ¹H-¹⁵N spectrum of KlcA₁₃₆, two weak peaks were observed at ¹⁵N chemical shifts of 69 and 72 ppm. A F₁ ¹H-coupled ¹H-¹⁵N HSQC showed that these signals belong to NH₂ moieties. The ¹⁵N chemical shifts are consistent with values reported for the guanidinium moiety of arginine from BioMagResBank (74). These NH₂ groups would normally undergo chemical exchange with water and thus not be observed. The fact that they are present in the spectrum indicates reduced chemical exchange and suggests that these are involved in H-bonded salt bridges. Examination of the 3D structure of the protein, indicates

that the N^η₂ of R73 (one residue before strand D) and O^ε₂ of E86 (strand E) are separated by 2.97 Å, while this distance is 4.47 Å for R48 (loop) and E75 (strand D). The former pair meets the criterion (3.5 Å) for a H-bonded salt bridge interaction (75). Based on this analysis the ¹⁵N peaks with chemical shifts of 69 and 72 ppm were tentatively assigned to NH₂ moieties of R48 and R73. Our relaxation data, described below, indicate that the D and E strands are the most flexible on the fast time scale, so a H-bonded salt bridge could stabilise these relatively short β -strands. The second interaction could potentially maintain the relative orientation between the helix 2 and strands D and E, which connect to the rest of the protein via loops.

The measured ¹⁵N longitudinal T₁ and transverse T₂ relaxation times and steady state ¹H-¹⁵N NOEs were measured (Supplementary Figure S3). Due to spectral overlap, only 113 of the 137 non-proline residues of the protein could be used for the calculation of the relaxation parameters. The residues with higher amplitude of internal motions have simultaneously higher values of T₁ and T₂. In contrast, amide groups with the simultaneously lowest values of T₁ and T₂ values belong to the residues with the most restricted local mobility. Heteronuclear NOE values < 0.68 were used to identify residues of the protein that are dynamic on the ps–ns timescale. As the majority of heteronuclear NOEs are > 0.68, the backbone exhibits limited motions on this timescale (76). The only exceptions were residues 3–6 that exhibited negative NOE values indicating a flexible N-terminus.

The presence of internal motion and chemical exchange can lead to distortions of the T₁/T₂ ratio, and therefore the collection of residues used to determine the diffusion properties of the entire molecule excluded mobile

residues or those exhibiting slow exchange broadening. A subset of 97 residues was used in the determination of the diffusion tensor. In this subset the average values of T_1 and T_2 were 737 and 86 ms, respectively. The relative moments of inertia values were found to be I_z : 1.00, I_y : 0.9858 and I_x : 0.8629. I_y and I_x are very close to 1.00, implying that the protein does not deviate significantly from a sphere, having slightly oblate shape. Given the nearly spherical shape, an isotropic diffusion tensor with a $D_{\text{iso}} = 1.8 \times 10^7 \text{ s}^{-1}$ was calculated and the average rotational correlation time (τ_c) was found to be $8.83 \text{ ns} \pm 0.01$, a value expected for a protein of this size.

In order to extract microscopic parameters of motion from the relaxation data a model-free approach was used, which assumes the overall and internal motions of the molecule are independent. Based on the above analysis of the relaxation data, an isotropic model was selected. Relaxation data for most residues (73%) were adequately described by the generalized order parameter S^2 suggesting a rigid molecule overall. The order parameter is a measure of the degree of spatial motion of the N–H bond where a value of zero means that the bond vector has unrestricted motion while one implies a completely rigid bond. An additional parameter (R_{ex}) was required to fit 17 residues, with residues A14, A16, A91, E107, I108, L117 and Y121 showing significant R_{ex} values ($>2 \text{ Hz}$), suggesting that these N–H sites experience multiple environments interconverting on the micro- to millisecond time scale. Eleven residues (E4, M31, V38, W41, E47, Y56, F64, F99, Q103, F123 and A128) did not fit the model. The order parameter S^2 as a function of the residue number is shown in Supplementary Figure S3. The distribution of S^2 values visualized on the structure shows that the mobility on the nanosecond time scale is slightly restricted in secondary structure elements compared to loops (Supplementary Figure S4). The

largest mobility indicated by the smallest S^2 values was observed with residues at the N-terminus and with residues between the end of strand C and the start of helix 3.

The surface of KlcA₁₃₆ reveals charged and hydrophobic patches but little sequence conservation for residues in these patches

An electrostatic surface representation generated by GRASP shows that the surface of KlcA₁₃₆ is predominantly negatively charged, consistent with its theoretical pI (4.76), Figure 8. The negatively charged side-chain residues on the KlcA₁₃₆ surface reveals two distinct clusters (i) an ‘Aspartate cluster’ made up of five linearly arranged residues i.e. D61 (in the loop between β -strands B and C), D110, D112, D115, D119 (in the loop between α -helix 3 and 4 and on α -helix 4) and (ii) a ‘Glutamate cluster’ that contains amino acid residues E47 (in the loop between α -helix 2 and β -strand B), E75 and E77 (on β -strand D), E86 (on β -strand E) and E133 (on α -helix 5). In addition to the five residues present in the ‘Glutamate cluster’ are residues E15, D69 and D90, which are also located nearby in 3D space. A striking linear arrangement of positive charge involving arginine side-chains is also evident, predominantly on the opposite side of the KlcA₁₃₆ protein surface with respect to its negatively charged clusters. This ‘Arginine cluster’ contains seven residues: R29, R33, R43, R44 on α -helix 2, R48 in the loop between α -helix 2 and β -strand B, R84 on β -strand E and R120 on α -helix 4. Even though three distinct regions of charge are apparent from the electrostatic surface representations, only a handful of the charged residues are conserved in the 43 non-redundant sequences identified (Supplementary Figure S5). These include R18, E35, D61, D90, R125, E133 and D142.




Figure 8. Electrostatic surface representation of the KlcA₁₃₆ protein. Two views rotated by 180° about the y -axis of a GRASP electrostatic surface representation of the KlcA₁₃₆ protein. The molecule appears to expose many charged residues, labelled. Negative charge is coloured red and positive charge coloured blue, ranging from $-10 \text{ k}_B\text{T}$ to $+10 \text{ k}_B\text{T}$ (k_B : Boltzmann constant; T: temperature in Kelvin).




Figure 9. Lipophilic surface representation of the KlcA₁₃₆ protein. Two views, rotated by 180° about the y-axis, of a MOLCAD-generated lipophilic surface rendition of the protein. Regions of high lipophilicity or hydrophobicity are coloured brown and regions of high hydrophilicity are coloured blue.

Additionally, the lipophilic surface rendition generated by MOLCAD reveals two regions of spatially contiguous hydrophobic side-chains on one face of the molecule, Figure 9 (left-hand panel) and another more prominent hydrophobic region on the opposite face of the protein, Figure 9 (right-hand panel). Among these, F21, L22, W54, F83, L87, A128 and I141 are largely conserved. Some of the aromatic side-chains are involved in aromatic–aromatic stacking interactions e.g., F64 with F21, Y25, F26; Y57 with Y65, F127; Y39 with W54 and W41 with F99.

Comparisons between the 43 ArdB and KlcA protein sequences showed that they have highly conserved α -helices and β -strands, while loops vary in length and amino acid composition. Figure 10 shows a subset of the sequences comprised of the proteins listed in Table 1 and the archetypal KlcA from plasmid RK2 (20) and archetypal ArdB from pKM101 (11). Mapping sequence conservation (Supplementary Figure S5) onto the surface of KlcA136 shows only three well-conserved patches, comprising firstly H81 and D142, secondly L87, S88 and E133 and lastly E35, Y49, G51, A52 and W54, Figure 11. Only the first of these three patches projects out from the surface, the others are on concave regions of the surface.

Discussion

In this study, we have solved the atomic resolution structure of KlcA₁₃₆, an anti-restriction protein belonging to the ArdB family and showed its anti-restriction function against Type I RM systems. We have also demonstrated the same anti-restriction function for five other examples of the ArdB/KlcA family from a range of organisms.

A particularly striking result is the absence of any inhibition of a Type I RM enzyme *in vitro*. The EcoKI RM enzyme was able to bind and cleave unmodified DNA in the presence of either ArdB or KlcA proteins in contrast to the result *in vivo* in which the enzyme failed to operate against invading phage DNA in the presence of these anti-restriction proteins. Thus the ArdB/KlcA proteins must operate in a different manner to the DNA mimics. Several protein-based anti-restriction strategies aimed at negating the activity of Type I RM systems have been identified in addition to DNA mimicry (2), namely, hydrolysis of the essential *S*-adenosyl-L-methionine cofactor (77), proteolysis of the HsdR subunit required for DNA cleavage (30,32,71), enhancement of the Mtase activity via the action of the lambda *ral* gene to allow protection of unmethylated DNA targets (78) and interference with the subunit assembly process forming the complete RM enzyme (26). Our data and that of Belogurov *et al.* (11), who demonstrated that *ardB* did not stimulate DNA modification by the EcoKI Type I RM system using a *ral*-like mechanism, show that these mechanisms are not applicable to the ArdB/KlcA proteins. Thus the mechanism of anti-restriction by ArdB and KlcA remains unclear at present. However, the variable quaternary structure observed using size exclusion chromatography may suggest a role for large scale conformational changes in both tertiary and quaternary structure in ArdB and KlcA as being involved in anti-restriction.

The structure of KlcA₁₃₆ is the first ArdB/KlcA structure reported and adopts a novel fold. Although three distinct regions of charge are apparent from the electrostatic surface representation, only a handful of charged residues are conserved among the 43 non-redundant related sequences of the ArdB/KlcA group. Other anti-restriction proteins, such as ocr from




Figure 10. A PROMALS3D sequence alignment of KlcA and ArdB proteins. KlcA_RK2 and ArdB_pKM101 are the archetypal sequences for these two proteins (11,20). Yellow shading represents beta strands, red shading represents alpha helices and purple shading represents the 3₁₀ helix. The grey shading highlights the anti-restriction motif LLREYVNTL in ArdB from pKM101 (7,26). Consensus amino acid symbols are: conserved amino acids are in bold and uppercase letters; aliphatic (I, V, L): l; aromatic (Y, H, W, F): @; hydrophobic (W, F, Y, M, L, I, V, A, C, T, H): h; alcohol (S, T): o; polar residues (D, E, H, K, N, Q, R, S, T): p; tiny (A, G, C, S): t; small (A, G, C, S, V, N, D, T, P): s; bulky residues (E, F, I, K, L, M, Q, R, W, Y): b; positively charged (K, R, H): +; negatively charged (D, E): -; charged (D, E, K, R, H): c.




Figure 11. Sequence conservation mapped onto KlcA₁₃₆ protein surface. Conservation surface representation based upon the PROMALS3D multiple sequence alignment of ArdB and KlcA sequences (Supplementary Figure S5) where largely and completely conserved residues are shown in lavender/plum/violet colour mapped onto the surface and variable residue positions coloured cyan.

phage T7 (9) and ArdA from the conjugative transposon Tn916 (8), have been shown to comprise elongated structures that bind to DNA binding site of the Mtase core of the Type I RM enzyme, thereby rendering the enzyme incapable of recognizing its DNA target both *in vivo* and *in vitro*. The structure of KlcA₁₃₆ on the other hand, appears to be a rigid globular molecule of novel fold and does not mimic double-stranded DNA.

ACCESSION NUMBER

2 kmg.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS

We thank Dr Patrick Langridge-Smith for access to the SIRCAMS FTICR-MS facility supported by the RASOR grant from the BBSRC (BB/C511599/1) and Drs Logan Mackay and David Clarke for running the FT-ICR MS.

FUNDING

The Biotechnology and Biological Sciences Research Council (BB/D001870/1 to D.T.F.D.); The Wellcome Trust (GR080463MA to D.T.F.D., G.W.B., Malcolm Walkinshaw and James Naismith, and G078780/Z/05/Z to D.U. and A.P.H.); The Engineering and Physical Sciences Research Council (studentship for D.S.M.); Wellcome Trust, BBSRC, Scottish Universities Life Science Alliance and The University of Edinburgh (to D.C.S. who is a part of Centre for Translational and Chemical Biology); RASOR grant from the BBSRC (BB/C511599/1 to Dr Patrick Langridge-Smith for access to the SIRCAMS FTICR-MS facility); Funding for open access charge: The Wellcome Trust.

Conflict of interest statement. None declared.

REFERENCES

- Thomas, C.M. and Nielsen, K.M. (2005) Mechanisms of, and barriers to, horizontal gene transfer between bacteria. *Nat. Rev.*, **3**, 711–721.
- Tock, M.R. and Dryden, D.T.F. (2005) The biology of restriction and anti-restriction. *Curr. Opin. Microbiol.*, **8**, 466–472.
- Wilkins, B.M. (2002) Plasmid promiscuity: meeting the challenge of DNA immigration control. *Env. Microbiol.*, **4**, 495–500.
- Murray, N.E. (2000) Type I restriction systems: sophisticated molecular machines (a legacy of Bertani and Weigle). *Microbiol. Mol. Biol. Rev.*, **64**, 412–434.
- Roberts, R.J., Vincze, T., Posfai, J. and Macelis, D. (2007) REBASE—enzymes and genes for DNA restriction and modification. *Nucleic Acids Res.*, **35**, D269–D270.
- Webb, J.L., King, G., Ternent, D., Titheradge, A.J. and Murray, N.E. (1996) Restriction by EcoKI is enhanced by co-operative interactions between target sequences and is dependent on DEAD box motifs. *EMBO J.*, **15**, 2003–2009.
- Zavilgelsky, G.B. (2000) Antirestriction. *Mol. Biol.*, **34**, 724–732.
- McMahon, S.A., Roberts, G.A., Johnson, K.A., Cooper, L.P., Liu, H., White, J.H., Carter, L.G., Sanghvi, B., Oke, M., Walkinshaw, M.D. *et al.* (2009) Extensive DNA mimicry by the ArdA anti-restriction protein and its role in the spread of antibiotic resistance. *Nucleic Acids Res.*, **37**, 4887–4897.
- Walkinshaw, M.D., Taylor, P., Sturrock, S.S., Atanasiu, C., Berge, T., Henderson, R.M., Edwardson, J.M. and Dryden, D.T.F. (2002) Structure of Ocr from bacteriophage T7, a protein that mimics B-form DNA. *Mol. Cell*, **9**, 187–194.
- Stephanou, A.S., Roberts, G.A., Tock, M.R., Pritchard, E.H., Turkington, R., Nutley, M., Cooper, A. and Dryden, D.T.F. (2009) A mutational analysis of DNA mimicry by ocr, the gene 0.3 antirestriction protein of bacteriophage T7. *Biochem. Biophys. Res. Commun.*, **378**, 129–132.
- Belogurov, A.A., Delver, E.P. and Rodzevich, O.V. (1993) Plasmid pKM101 encodes two nonhomologous antirestriction proteins (ArdA and ArdB) whose expression is controlled by homologous regulatory sequences. *J. Bacteriol.*, **175**, 4843–4850.
- Nekrasov, S.V., Agafonova, O.V., Belogurova, N.G., Delver, E.P. and Belogurov, A.A. (2007) Plasmid-encoded antirestriction protein ArdA can discriminate between type I methyltransferase and complete restriction-modification system. *J. Mol. Biol.*, **365**, 284–297.
- Serfiotis-Mitsa, D., Roberts, G.A., Cooper, L.P., White, J.H., Nutley, M., Cooper, A., Blakely, G.W. and Dryden, D.T.F. (2008) The Orf18 gene product from conjugative transposon Tn916 is an ArdA antirestriction protein that inhibits type I DNA restriction-modification systems. *J. Mol. Biol.*, **383**, 970–981.
- Thomas, A.T., Brammar, W.J. and Wilkins, B.M. (2003) Plasmid R16 ArdA protein preferentially targets restriction activity of the type I restriction-modification system EcoKI. *J. Bacteriol.*, **185**, 2022–2025.
- Zavilgelsky, G.B., Kotova, V.Y. and Rastorguev, S.M. (2008) Comparative analysis of anti-restriction activities of ArdA (ColIb-P9) and Ocr (T7) proteins. *Biochemistry*, **73**, 906–911.
- Atanasiu, C., Su, T.J., Sturrock, S.S. and Dryden, D.T.F. (2002) Interaction of the ocr gene 0.3 protein of bacteriophage T7 with EcoKI restriction/modification enzyme. *Nucleic Acids Res.*, **30**, 3936–3944.
- Kennaway, C.K., Obarska-Kosinska, A., White, J.H., Tuszyńska, I., Cooper, L.P., Bujnicki, J.M., Trinick, J. and Dryden, D.T.F. (2009) The structure of M.EcoKI Type I DNA methyltransferase with a DNA mimic antirestriction protein. *Nucleic Acids Res.*, **37**, 762–770.
- Belogurov, A.A., Delver, E.P., Agafonova, O.V., Belogurova, N.G., Lee, L.Y. and Kado, C.I. (2000) Antirestriction protein Ard (Type C) encoded by IncW plasmid pSa has a high similarity to the “protein transport” domain of TraC1 primase of promiscuous plasmid RP4. *J. Mol. Biol.*, **296**, 969–977.
- Kamachi, K., Sota, M., Tamai, Y., Nagata, N., Konda, T., Inoue, T., Top, E.M. and Arakawa, Y. (2006) Plasmid pBP136 from *Bordetella pertussis* represents an ancestral form of IncP-1beta plasmids without accessory mobile elements. *Microbiology*, **152**, 3477–3484.
- Larsen, M.H. and Figurski, D.H. (1994) Structure, expression, and regulation of the kilC operon of promiscuous IncP alpha plasmids. *J. Bacteriol.*, **176**, 5022–5032.
- Riley, M., Abe, T., Arnaud, M.B., Berlyn, M.K., Blattner, F.R., Chaudhuri, R.R., Glasner, J.D., Horiuchi, T., Keseler, I.M., Kosuge, T. *et al.* (2006) Escherichia coli K-12: a cooperatively developed annotation snapshot—2005. *Nucleic Acids Res.*, **34**, 1–9.
- Rasko, D.A., Phillips, J.A., Li, X. and Mobley, H.L. (2001) Identification of DNA sequences from a second pathogenicity island of uropathogenic Escherichia coli CFT073: probes specific for uropathogenic populations. *J. Infectious Diseases*, **184**, 1041–1049.
- Welch, R.A., Burland, V., Plunkett, G. III, Redford, P., Roesch, P., Rasko, D., Buckles, E.L., Liou, S.R., Boutin, A., Hackett, J. *et al.* (2002) Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. *Proc. Natl Acad. Sci. USA*, **99**, 17020–17024.
- Cazalet, C., Rusniok, C., Bruggemann, H., Zidane, N., Magnier, A., Ma, L., Tichit, M., Jarraud, S., Bouchier, C., Vandenesch, F. *et al.* (2004) Evidence in the *Legionella pneumophila* genome for

- exploitation of host cell functions and high genome plasticity. *Nat. Genet.*, **36**, 1165–1173.
25. Vedler, E., Vahter, M. and Heinaru, A. (2004) The completely sequenced plasmid pEST4011 contains a novel IncP1 backbone and a catabolic transposon harboring *tfd* genes for 2,4-dichlorophenoxyacetic acid degradation. *J. Bacteriol.*, **186**, 7161–7174.
 26. Belogurov, A.A. and Delver, E.P. (1995) A motif conserved among the type I restriction-modification enzymes and antirestriction proteins: a possible basis for mechanism of action of plasmid-encoded antirestriction functions. *Nucleic Acids Res.*, **23**, 785–787.
 27. Adamczyk, M. and Jagura-Burdzy, G. (2003) Spread and survival of promiscuous IncP-1 plasmids. *Acta Biochimica Polonica*, **50**, 425–453.
 28. Burlage, R.S., Bemis, L.A., Layton, A.C., Sayler, G.S. and Larimer, F. (1990) Comparative genetic organization of incompatibility group P degradative plasmids. *J. Bacteriol.*, **172**, 6818–6825.
 29. Harada, K.M., Aso, Y., Hashimoto, W., Mikami, B. and Murata, K. (2006) Sequence and analysis of the 46.6-kb plasmid pA1 from *Sphingomonas* sp. A1 that corresponds to the typical IncP-1beta plasmid backbone without any accessory gene. *Plasmid*, **56**, 11–23.
 30. Blakely, G.W. and Murray, N.E. (2006) Control of the endonuclease activity of type I restriction-modification systems is required to maintain chromosome integrity following homologous recombination. *Mol. Microbiol.*, **60**, 883–893.
 31. Gill, S.C. and von Hippel, P.H. (1989) Calculation of protein extinction coefficients from amino acid sequence data. *Anal. Biochem.*, **182**, 319–326.
 32. Makovets, S., Powell, L.M., Titheradge, A.J., Blakely, G.W. and Murray, N.E. (2004) Is modification sufficient to protect a bacterial chromosome from a resident restriction endonuclease? *Mol. Microbiol.*, **51**, 135–147.
 33. Stephanou, A.S., Roberts, G.A., Cooper, L.P., Clarke, D.J., Thomson, A.R., MacKay, C.L., Nutley, M., Cooper, A. and Dryden, D.T.F. (2009) Dissection of the DNA mimicry of the bacteriophage T7 Ocr protein using chemical modification. *J. Mol. Biol.*, **391**, 565–576.
 34. Dryden, D.T.F., Cooper, L.P., Thorpe, P.H. and Byron, O. (1997) The in vitro assembly of the EcoKI type I DNA restriction/modification enzyme and its in vivo implications. *Biochemistry*, **36**, 1065–1076.
 35. Uhrinova, S., Uhrin, D., Denton, H., Smith, M., Sawyer, L. and Barlow, P.N. (1998) Complete assignment of ¹H, ¹³C and ¹⁵N chemical shifts for bovine beta-lactoglobulin: secondary structure and topology of the native state is retained in a partially unfolded form. *J. Biomol. NMR*, **12**, 89–107.
 36. Muhandiram, D.R., Farrow, N.A., Xu, G.Y., Smallcombe, S.H. and Kay, L.E. (1993) A gradient C-13 Noesy-Hsqc experiment for recording Noesy spectra of C-13-labeled proteins dissolved in H₂O. *J. Mag. Res. Series B*, **102**, 317–321.
 37. Sklenar, V., Piotto, M., Leppik, R. and Saudek, V. (1993) Gradient-tailored water suppression for H-1-N-15 Hsqc experiments optimized to retain full sensitivity. *J. Mag. Res. Series A*, **102**, 241–245.
 38. Yamazaki, T., Forman-Kay, J.D. and Kay, L.E. (1993) Two-dimensional NMR experiments for correlating ¹³Cβ and ¹Hδ/ε chemical shifts of aromatic residues in ¹³C-labeled proteins via scalar couplings. *J. Am. Chem. Soc.*, **115**, 11054–11055.
 39. Vranken, W.F., Boucher, W., Stevens, T.J., Fogh, R.H., Pajon, A., Llinas, M., Ulrich, E.L., Markley, J.L., Ionides, J. and Laue, E.D. (2005) The CCPN data model for NMR spectroscopy: development of a software pipeline. *Proteins*, **59**, 687–696.
 40. Herrmann, T., Guntert, P. and Wuthrich, K. (2002) Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA. *J. Mol. Biol.*, **319**, 209–227.
 41. Guntert, P. (2004) Automated NMR structure calculation with CYANA. *Methods Mol. Biol.*, **278**, 353–378.
 42. Cornilescu, G., Delaglio, F. and Bax, A. (1999) Protein backbone angle restraints from searching a database for chemical shift and sequence homology. *J. Biomol. NMR*, **13**, 289–302.
 43. Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S. et al. (1998) Crystallography & NMR system: a new software suite for macromolecular structure determination. *Acta Crystallogr.*, **54**, 905–921.
 44. Laskowski, R.A., Rullmann, J.A., MacArthur, M.W., Kaptein, R. and Thornton, J.M. (1996) AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. *J. Biomol. NMR*, **8**, 477–486.
 45. Vriend, G. (1990) What if - a molecular modeling and drug design program. *J. Mol. Graphics*, **8**, 52–56.
 46. Koradi, R., Billeter, M. and Wuthrich, K. (1996) MOLMOL: a program for display and analysis of macromolecular structures. *J. Mol. Graphics*, **14**, 51–55, 29–32.
 47. Otting, M., Delaglio, F. and Bax, A. (1998) Measurement of J and dipolar couplings from simplified two-dimensional NMR spectra. *J. Magn. Reson.*, **131**, 373–378.
 48. Valafar, H. and Prestegard, J.H. (2004) REDCAT: a residual dipolar coupling analysis tool. *J. Magn. Reson.*, **167**, 228–241.
 49. Grzesiek, S. and Bax, A. (1993) The importance of not saturating water in protein NMR. Application to sensitivity enhancement and NOE measurements. *J. Am. Chem. Soc.*, **115**, 12593–12594.
 50. Yip, G.N. and Zuiderweg, E.R. (2005) Improvement of duty-cycle heating compensation in NMR spin relaxation experiments. *J. Magn. Reson.*, **176**, 171–178.
 51. Dosset, P., Hus, J.C., Blackledge, M. and Marion, D. (2000) Efficient analysis of macromolecular rotational diffusion from heteronuclear relaxation data. *J. Biomol. NMR*, **16**, 23–28.
 52. Tjandra, N., Feller, S.E., Pastor, R.W. and Bax, A. (1995) Rotational diffusion anisotropy of human ubiquitin from ¹⁵N NMR relaxation. *J. Am. Chem. Soc.*, **117**, 12562–12566.
 53. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N. and Bourne, P.E. (2000) The Protein Data Bank. *Nucleic Acids Res.*, **28**, 235–242.
 54. Frishman, D. and Argos, P. (1995) Knowledge-based protein secondary structure assignment. *Proteins*, **23**, 566–579.
 55. Hutchinson, E.G. and Thornton, J.M. (1990) HERA—a program to draw schematic diagrams of protein secondary structures. *Proteins*, **8**, 203–212.
 56. Hutchinson, E.G. and Thornton, J.M. (1996) PROMOTIF—a program to identify and analyze structural motifs in proteins. *Protein Sci.*, **5**, 212–220.
 57. Bond, C.S. (2003) TopDraw: a sketchpad for protein structure topology cartoons. *Bioinformatics*, **19**, 311–312.
 58. Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W. and Lipman, D.J. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.*, **25**, 3389–3402.
 59. Bennett-Lovsey, R.M., Herbert, A.D., Sternberg, M.J. and Kelley, L.A. (2008) Exploring the extremes of sequence/structure space with ensemble fold recognition in the program Phyre. *Proteins*, **70**, 611–625.
 60. Holm, L. and Sander, C. (1993) Protein structure comparison by alignment of distance matrices. *J. Mol. Biol.*, **233**, 123–138.
 61. Krissinel, E. and Henrick, K. (2004) Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. *Acta Crystallogr.*, **60**, 2256–2268.
 62. Bairoch, A., Apweiler, R., Wu, C.H., Barker, W.C., Boeckmann, B., Ferro, S., Gasteiger, E., Huang, H., Lopez, R., Magrane, M. et al. (2005) The Universal Protein Resource (UniProt). *Nucleic Acids Res.*, **33**, D154–159.
 63. Combet, C., Blanchet, C., Geourjon, C. and Deleage, G. (2000) NPS@: network protein sequence analysis. *Trends Biochem. Sci.*, **25**, 147–150.
 64. Pei, J., Kim, B.H. and Grishin, N.V. (2008) PROMALS3D: a tool for multiple protein sequence and structure alignments. *Nucleic Acids Res.*, **36**, 2295–2300.
 65. Glaser, F., Pupko, T., Paz, I., Bell, R.E., Bechor-Shental, D., Martz, E. and Ben-Tal, N. (2003) ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. *Bioinformatics*, **19**, 163–164.
 66. Nicholls, A., Sharp, K.A. and Honig, B. (1991) Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. *Proteins*, **11**, 281–296.

67. Heiden, W., Moeckel, G. and Brickmann, J. (1993) A new approach to analysis and display of local lipophilicity hydrophilicity mapped on molecular-surfaces. *J. Comput. Aided Mol. Des.*, **7**, 503–514.
68. Fraczekiewicz, R. and Braun, W. (1998) Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules. *J. Comp. Chem.*, **19**, 319–333.
69. Saltman, L.H., Kim, K.S. and Figurski, D.H. (1991) The *kilA* operon of promiscuous plasmid RK2: the use of a transducing phage (*lambda* *pklaA-1*) to determine the effects of the lethal *klaA* gene on *Escherichia coli* cells. *Mol. Microbiol.*, **5**, 2673–2683.
70. Dunn, J.J., Elzinga, M., Mark, K.K. and Studier, F.W. (1981) Amino acid sequence of the gene 0.3 protein of bacteriophage T7 and nucleotide sequence of its mRNA. *J. Biol. Chem.*, **256**, 2579–2585.
71. Makovets, S., Doronina, V.A. and Murray, N.E. (1999) Regulation of endonuclease activity by proteolysis prevents breakage of unmodified bacterial chromosomes by type I restriction enzymes. *Proc. Natl Acad. Sci. USA*, **96**, 9757–9762.
72. Bandyopadhyay, P.K., Studier, F.W., Hamilton, D.L. and Yuan, R. (1985) Inhibition of the type I restriction-modification enzymes EcoB and EcoK by the gene 0.3 protein of bacteriophage T7. *J. Mol. Biol.*, **182**, 567–578.
73. Alexandrov, N. and Shindyalov, I. (2003) PDP: protein domain parser. *Bioinformatics*, **19**, 429–430.
74. Ulrich, E.L., Akutsu, H., Doreleijers, J.F., Harano, Y., Ioannidis, Y.E., Lin, J., Livny, M., Mading, S., Maziuk, D., Miller, Z. *et al.* (2008) BioMagResBank. *Nucleic Acids Res.*, **36**, D402–408.
75. Kumar, S. and Nussinov, R. (1999) Salt bridge stability in monomeric proteins. *J. Mol. Biol.*, **293**, 1241–1255.
76. Kay, L.E., Torchia, D.A. and Bax, A. (1989) Backbone dynamics of proteins as studied by ¹⁵N inverse detected heteronuclear NMR spectroscopy: application to staphylococcal nuclease. *Biochemistry*, **28**, 8972–8979.
77. Studier, F.W. and Movva, N.R. (1976) SAMase gene of bacteriophage T3 is responsible for overcoming host restriction. *J. Virol.*, **19**, 136–145.
78. Loenen, W.A. and Murray, N.E. (1986) Modification enhancement by the restriction alleviation protein (Ral) of bacteriophage *lambda*. *J. Mol. Biol.*, **190**, 11–22.